Clinical applications of angiogenic growth factors and their inhibitors

Nature Medicine

Volumn 5, Issue 12, 1999, Pages 1359-1364

  Ferrara, Napoleone ^a   Alitalo, Kari ^b  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; MONOCLONAL ANTIBODY; PROTEIN INHIBITOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTERY OCCLUSION; CLINICAL MEDICINE; HUMAN; ISCHEMIA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA ISCHEMIA; REVIEW; SOLID TUMOR;

ANIMALS; CORONARY DISEASE; ENDOTHELIAL GROWTH FACTORS; GROWTH INHIBITORS; HUMANS; ISCHEMIA; LYMPHOKINES; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT PROTEINS; RETINAL VEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032710319     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/70928     Document Type: Review

References (97)

1. Risau, W. Mechanisms of angiogenesis. Nature 386, 671-674 (1997).
2. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med. 1, 27-31 (1995).
3. Korpelainen, E.I. & Alitalo, K. Signaling angiogenesis and lymphangiogenesis. Curr. Opin. Cell Biol. 10, 159-164 (1998).
4. Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25 (1997).
5. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442 (1996).
6. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996).
7. Carmeliet, P. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelila growth factor isoforms VEGF164 and VEGF188. Nature Med. 5, 495-502 (1999).
8. Seghezzi, G. et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 171, 1659-1673 (1998).
9. Rivard, A. & Isner, J.M. Angiogenesis and vasculogenesis in treatment of cardiovascular disease. Mol. Med. 4, 429-440 (1998).
10. Takeshita, S. et al. Therapeutic angiogenesis. A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93, 662-670 (1994).
11. Pu, L.Q. et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 88, 208-215 (1993).
12. Asahara, T. et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92, II365-II371 (1995).
13. Van Belle, E. et al. Potentiated angiogenic effect of scatter factor hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97, 381-390 (1998).
14. Witzenbichler, B. et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 153, 361-394 (1998).
15. Bauters, C. et al. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am. J. Physiol. 267, H1263-H1271 (1994).
16. Takeshita, S. et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab. Invest. 75, 487-501 (1996).
17. Mack, C.A. et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion, J. Vasc. Surg. 27, 699-709 (1998).
18. Pearlman, J.D. et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nature Med. 1, 1085-1089 (1995).
19. Harada, K. et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J. Clin. Invest. 94, 623-630 (1994).
20. Lopez, J.J. et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc. Res. 40, 272-281 (1998).
21. Li, J. et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am. J. Physiol. 270, H1803-H1811 (1996).
22. Mack, C.A. et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J. Thor. Cardiovasc. Surg. 115, 168-176 (1998).
23. Giordano, F. et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat. Med. 2, 534-539 (1996).
24. Isner, J.M. et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348, 370-374 (1996).
25. Baumgartner, I. et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97, 1114-1123 (1998).
26. Losordo, D.W. et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98, 2800-2804 (1998).
27. Isner, J.M. et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J. Vasc. Surg. 28, 964-975 (1998).
28. Henry, T.D. et al. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial. J. Am. Coll. Cardiol. 31, 65A (810-811) (1998).
29. Henry, T.D. et al. Double blind, placebo controlled, trial of recombinant human vascular endothelial growth factor: the VIVA trial. J. Am. Coll. Cardiol. 33, 384A 874 (1999).
30. Bittl, J.A. Advances in coronary angioplasty. N. Engl. J. Med. 335, 1290-1302 (1996).
31. Yla-Herttuala, S. Vascular gene transfer. Curr. Opin. Lipidol. 8, 72-76 (1997).
32. Asahara, T. et al. Local delivery of vascular endothelial growth factor accelerates re-endothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 91, 2793-2801 (1995).
33. Burke, P.A., Lehmann-Bruinsma, K. & Powell, J.S. Vascular endothelial growth factor causes endothelial proliferation after vascular injury. Biochem. Biophys. Res. Comm. 207, 348-354 (1995).
34. Laitinen, M. et al. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum. Gene Ther. 8, 1737-1744 (1997).
35. Laitinen, M. et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum. Gene Ther. 9, 1481-1486 (1998).
36. Camenzind, E. et al. Intracoronary heparin delivery in humans. Acute feasibility and long-term results. Circulation 92, 2463-2472 (1995).
37. Greelish, J.P. et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nature Med. 5, 439-443 (1999).
38. Hiltunen, M.O. et al. Intravascular Adenovirus-mediated VEGF-C gene transfer inhibits neointima formation in valloon-denuded rabbit aorta. Circulation (in press).
39. Algire, G.H. & Chalkley, H.W. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J. Natl. Cancer Inst. 6, 73-85 (1945).
40. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
41. Ensoli, B. et al. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. J. Clin. Invest. 94, 1736-1746 (1994).
42. Lin, P. et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 100, 2072-2078 (1997).
43. Lin, P. et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. USA 95, 8829-8834 (1998).
44. Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715-725 (1998).
45. Gasparini, G. et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst. 89, 139-147 (1997).
46. Maeda, K. et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77, 853-863 (1996).
47. Salven, P., Ruotsalainen, T., Mattson, K. & Joensuu, H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int. J. Cancer 79, 144-146 (1998).
48. Kim, K.J. et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
49. Borgström, P., Hillan, K.J., Sriramarao, P. & Ferrara, N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56, 4032-4039 (1996).
50. Yuan, F, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 93, 14765-14770 (1996).
51. Millauer, B. et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56, 1615-1620 (1996).
52. Kong, H.L. et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum. Gene Ther. 9, 823-833 (1998).
53. Goldman, C.K. et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA 95, 8795-8800 (1998).
54. Presta, L.G. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997).
55. Ryan, A.M. et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol. 27, 78-86, 1999.
56. Strawn, L.M. et al. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56, 3540-3545 (1996).
57. Patz, A. Studies on retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 19, 1133-1138 (1980).
58. Aiello, L.P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480-1487 (1994).
59. Adamis, A.P. et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114, 66-71 (1996).
60. Aiello, L.P. et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 92, 10457-10461 (1995).
61. Smith, L.E. et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276, 5319-5321 (1997).
62. Garner, A. in Pathobiology of Ocular Diseases 2nd edn. (eds. Garner, A. & Klintworth, G.K.) 1625-1710 (Marcel Dekker, New York, 1994).
63. Lopez, P.F., Sippy, B.D., Lambert, H.M., Thach, A.B. & Hinton, D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 37, 855-868 (1996).
64. Ruckman, J. et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556-20567 (1998).
65. van Bruggen, N. et al. VEGF antagonism reduces cerebral edema formation and tissue damage following ischemic-reperfusion injury in the mouse brain. J. Clin. Inv. (in the press).
66. Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Med. 4, 336-340 (1998).
67. McClure, N. et al. Vascular endothelial growth factor as a capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 344, 235-269, 1994.
68. Soker, S., Takashima, S., Miao, H.Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745 (1998).
69. Adams, R.H. et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 13, 295-306 (1999).
70. Wang, H.U., Chen, Z.-F. & Anderson, D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 741-753 (1998).
71. Shyu, K.-G., Manor, O., Magner, M., Yancopoulos, G.D. & Isner, J.M. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98, 2081-2087 (1998).
72. Roelen, B.A. & van Rooijen, M.A. Mummery CL. Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev. Dyn. 209, 418-430 (1997)
73. Uyttendaele, H. et al. Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development 122, 2251-2259 (1996).
74. Jain, R.K. Delivery of molecular and cellular medicine to solid tumors. J. Control. Release 53, 49-67 (1998).
75. Carmeliet, P. et al. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998).
76. Albini, A. et al. The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat. Med. 2, 1371-1375 (1996).
77. Bais, C. et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391, 86-89, 1998.
78. Ogawa, S. et al. A novel type of vascular endothelial growth factor: VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273, 31273-31282 (1998).
79. Meyer, M. et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18, 363-374 (1999).
80. Wise, L.M. et al. Vascular endothelial growth factor (VEGF) -like protein from orf virus NZ2 binds to VEGFR2 and Neuropilin-1. Proc. Natl. Acad. Sci. 96, 3071-3076 (1999).
81. Suri, C. et al. Increased vascularization in mice overexpressing angiopoietin-1, Science 282, 468-471 (1998).
82. Asahara, T. et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res. 83, 233-240 (1998).
83. Springer, M.L,. Chen, A.S., Kraft, P.E., Bednarski, M. & Blau, H.M. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell 2, 549-558 (1998).
84. Jeltsch, M. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276, 1423-1425 (1997).
85. Oh, S.J. et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev. Biol. 188, 96-109 (1997).
86. Pham, C.D. et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest. 16, 225-230 (1998).
87. Gerber, H.P. et al. VEGF is required for growth and survival in neonatal mice. Development. 126, 1149-1159 (1999).
88. Benjamin, L., Hemo, I. & Keshet, E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591-1598 (1998).
89. Gerber, H. P. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med., 5, 623-628 (1999).
90. 165 mediates glomerular endothelial repair. J. Clin Invest. 104, 913-923 (1999).
91. Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
92. Shi, Q. et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92, 362-367 (1998).
93. Ziegler, B.L. et al. KDR receptor: a key marker defining hematopoietic stem cells. Science 285, 1553-1558 (1999).
94. Takahashi, T. et al. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nature Med. 5, 434-438 (1999).
95. 1 in the activation of vascular endothelial growth factor receptor-2. EMBO J. 18, 882-892 (1999).
96. Carmeliet, P. et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98, 147-157 (1999).
97. Ferrell, R.E. et al. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum. Mol. Genet. 7, 2073-2078 (1998).